Metraipolis › archive › dc_afc02beafd08
Benefits of SGLT2 inhibitors in patients with diabetes and advanced chronic kidney disease - where have we gone so far? — Europe PMC PMID:41635419
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41635419
- DOI
- 10.3389/fcdhc.2025.1759340
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T17:13:00.685Z
- SHA-256 of the archived text
a04e0fb0bc9a0840dd82474ad34ab0f05e9696fae9fa8cba53010e8cb91a2645- Stable URL of this page
https://metraipolis.com/documento/dc_afc02beafd08
How to cite
Benefits of SGLT2 inhibitors in patients with diabetes and advanced chronic kidney disease - where have we gone so far? — Europe PMC PMID:41635419 — Europe PMC (en), https://europepmc.org/article/MED/41635419 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_afc02beafd08 (Metraipolis archive dc_afc02beafd08, sha256 a04e0fb0bc9a0840dd82474ad34ab0f05e9696fae9fa8cba53010e8cb91a2645)
BibTeX
@misc{dcafc02beafd08,
title = {Benefits of SGLT2 inhibitors in patients with diabetes and advanced chronic kidney disease - where have we gone so far? — Europe PMC PMID:41635419},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41635419},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_afc02beafd08; sha256 a04e0fb0bc9a0840dd82474ad34ab0f05e9696fae9fa8cba53010e8cb91a2645},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41635419. Agents can read the archived copy with the MCP tool read_document.